What Is Retatrutide Approved For? Label Indications, Per the Research

Approval status, stated plainly

Retatrutide has no approved label indication anywhere. It is an investigational prescription medicine that, at the time of writing, had not received marketing authorisation from the US Food and Drug Administration, the European Medicines Agency, or any other national regulator for the treatment of obesity, type 2 diabetes, or any other condition. Because no regulator has issued a label, there is no approved indication, no approval date, and no approved population to describe. What exists instead is a published clinical trial record, beginning with phase 2 work describing retatrutide as a single peptide that acts as an agonist at the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors in people with type 2 diabetes (PMID 37385280).

This distinction matters because the phrase "approved for" has a narrow regulatory meaning. An approved indication is a condition, population and context of use that a regulator has reviewed and written into a product label after evaluating submitted efficacy and safety data. Trial participation, media coverage, and promising phase 3 results are not approvals. Reviews of the obesity pharmacotherapy pipeline have consistently classified retatrutide among agents in late-stage development rather than among marketed products (PMID 40022548), and systematic reviews of emerging obesity pharmacotherapies have placed it in the investigational category alongside other multi-receptor agonists (PMID 39952695).

Approved versus investigational: a status table

The table below separates regulatory status from trial status. Every row in the right-hand column describes what published studies have investigated, not what any authority has authorised.

What the type 2 diabetes trials examined

Phase 2

The phase 2 programme was the first substantial clinical description of retatrutide in people with type 2 diabetes. The study was a randomised, double-blind, placebo- and active-controlled, parallel-group trial conducted in the USA, in which once-weekly subcutaneous retatrutide was compared with placebo and with dulaglutide 1.5 mg over 36 weeks (PMID 37385280). Researchers reported dose-related reductions in glycated haemoglobin and in body weight across the retatrutide groups relative to placebo at the end of the treatment period, with gastrointestinal adverse events the most frequently recorded category (PMID 37385280). Phase 2 data of this kind support progression to larger trials; they do not constitute an approval, and the trial doses described there are trial protocol details rather than guidance for any individual.

Phase 3

Two phase 3 publications extended that record. TRANSCEND-T2D-1 was a double-blind, randomised phase 3 trial in people with type 2 diabetes and inadequate glycaemic control on diet and exercise alone, and the study reported efficacy and safety outcomes for retatrutide against comparator in that population (PMID 42250575). TRIUMPH-2 was a double-blind, parallel-group, randomised, placebo-controlled phase 3 trial in adults who had both obesity and type 2 diabetes, reporting weight and glycaemic outcomes alongside tolerability data (PMID 42810372). Publication of positive phase 3 results is one input into a regulatory submission; the submission, review and labelling steps follow separately, and none of those steps had produced an approved indication for retatrutide at the time of writing.

The registrational obesity programme

The TRIUMPH trials were designed as the registrational package for obesity and obesity-related conditions. A design and rationale paper described the programme as evaluating retatrutide in obesity, in obstructive sleep apnoea, and in knee osteoarthritis, with the trial populations and endpoints structured to support regulatory review in those settings (PMID 41090431). The existence of a registrational programme is a statement of intent by a sponsor, not a licence: the conditions named in those protocols are the indications a sponsor has chosen to pursue, and whether any of them ultimately appears on a label depends on how regulators assess the completed data.

Broader reviews have placed this triple-agonist strategy in context. Narrative reviews of triple agonism for obesity have grouped retatrutide with other agents that engage more than two incretin or metabolic receptors, describing the rationale for combining glucagon receptor activity with incretin activity (PMID 40741227). Pipeline reviews of future obesity medications have likewise catalogued retatrutide among investigational candidates rather than among approved options (PMID 38302593).

Uses discussed in the literature that are not approved indications

Several conditions appear in review articles that mention retatrutide. None of them is an approved indication, and the presence of a condition in a review is not evidence that a medicine works for it.

• Liver disease. Reviews of pharmacological development in NAFLD/MASLD have discussed incretin-based and multi-receptor agents among metabolic and liver-targeted interventions under evaluation (PMID 38681750).
• Multisystem outcomes. A review of obesity medications beyond weight loss summarised reported effects across cardiovascular, renal, hepatic and other organ systems for this drug class (PMID 42208956).
• Psychiatric conditions. A review examined whether GLP-1 receptor agonists might have a role in psychiatric illness, framing the question as an open research area rather than an established use (PMID 40042613).

Off-label prescribing is a concept that applies to medicines that already hold an approval somewhere; a clinician may prescribe an approved product for an unapproved purpose under professional judgement. Because retatrutide holds no approval, there is no label from which an off-label use could depart, and the published access route has been enrolment in clinical trials.

Safety and Tolerability: What Studies Report

Across the published trial record, gastrointestinal adverse events were the most commonly reported category. In the phase 2 type 2 diabetes trial, researchers reported that nausea, vomiting and diarrhoea occurred more often with retatrutide than with placebo and were generally related to dose escalation (PMID 37385280). The phase 3 TRANSCEND-T2D-1 trial reported safety alongside efficacy in its primary publication (PMID 42250575), and TRIUMPH-2 reported tolerability outcomes in adults with obesity and type 2 diabetes (PMID 42810372).

Class-level summaries describe a similar pattern for incretin-based medicines generally. A review of the efficacy and safety of GLP-1 medicines for type 2 diabetes and obesity summarised gastrointestinal intolerance as the dominant tolerability issue and discussed discontinuation and monitoring considerations for the class (PMID 38843460). A systematic review of emerging obesity pharmacotherapies made comparable observations about tolerability across investigational agents (PMID 39952695). Safety profiles described in trials reflect monitored, protocol-controlled settings; a full safety picture for any medicine is only defined once a regulator reviews the complete dataset and writes warnings, contraindications and monitoring requirements into a label.

How an indication becomes "approved"

Understanding the sequence clarifies why trial headlines and approvals are different things.

1. Phase 2. Dose-ranging and proof-of-concept data are generated, as in the US phase 2 type 2 diabetes trial (PMID 37385280).
2. Phase 3 registrational trials. Larger confirmatory trials test prespecified endpoints in defined populations, as described for the TRIUMPH programme (PMID 41090431).
3. Regulatory submission and review. A sponsor files a dossier; the regulator evaluates efficacy, safety, manufacturing and risk management.
4. Labelling. If approved, the regulator defines the indication, the population, warnings and administration details. Only at this point does an "approved for" statement exist.

Publication of phase 3 results for type 2 diabetes and obesity populations (PMID 42250575, PMID 42810372) places retatrutide at step two to three of that sequence as described in the literature cited here. Regulatory status can change, and the authoritative sources for current status are national regulator databases rather than secondary summaries.

Questions a prescribing clinician is positioned to answer

Decisions about treatment for obesity, type 2 diabetes, sleep apnoea or joint disease belong with a licensed physician who can review an individual's history. Reasonable topics for that conversation include which medicines currently hold approvals for the condition in question, what the published evidence shows for approved alternatives, how class-level gastrointestinal tolerability findings reported across incretin medicines might apply (PMID 38843460), and whether participation in an ongoing clinical trial is an option. This page is for educational purposes only and is not medical advice; consult a licensed physician about any medicine, any symptom, and any treatment decision.

Related reading

For a broader overview of the published evidence base, see the retatrutide learn page.

References

• Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA (Lancet, 2023)
• Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial (Lancet, 2026)
• Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial (Lancet, 2026)
• Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials (Diabetes, Obesity & Metabolism, 2026)
• Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity (Diabetes Care, 2024)
• The promise of glucagon-like peptide 1 receptor agonists (GLP-1RA) for the treatment of obesity: a look at phase 2 and 3 pipelines (Expert Opinion on Investigational Drugs, 2025)
• Emerging pharmacotherapies for obesity: A systematic review (Pharmacological Reviews, 2025)
• Triple Agonism Based Therapies for Obesity (Current Cardiovascular Risk Reports, 2025)
• What is the pipeline for future medications for obesity? (International Journal of Obesity, 2025)
• Beyond weight loss: multisystem benefits of obesity medications (The Lancet Diabetes & Endocrinology, 2026)
• Advancements in pharmacological treatment of NAFLD/MASLD: a focus on metabolic and liver-targeted interventions (Gastroenterology Report, 2024)
• Glucagon-like peptide-1 receptor agonists: a new pharmacological treatment option for psychiatric illnesses? (Der Nervenarzt, 2025)